CN102860496A - Oxidation-resisting health-care food for improving immunity and preparation method thereof - Google Patents
Oxidation-resisting health-care food for improving immunity and preparation method thereof Download PDFInfo
- Publication number
- CN102860496A CN102860496A CN2012103798847A CN201210379884A CN102860496A CN 102860496 A CN102860496 A CN 102860496A CN 2012103798847 A CN2012103798847 A CN 2012103798847A CN 201210379884 A CN201210379884 A CN 201210379884A CN 102860496 A CN102860496 A CN 102860496A
- Authority
- CN
- China
- Prior art keywords
- test
- oxidation
- group
- care food
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an oxidation-resisting health-care food for improving immunity. The oxidation-resisting health-care food comprises, by weight, 15-35% of Chinese wolfberry fruits, 15-35% of radix ophiopogonis, 10-30% of cordyceps sinensis, 10-30% of ginseng and 5-20% of schisandra chinensis. In addition, the invention further discloses a preparation method of the health-care food. The health-care food uses natural traditional Chinese medicines as raw materials, does not produce side effect while achieving the effects of improving the immunity and resisting oxidation and is suitable for all ages of people. The preparation method is simple and does not cause change of the raw materials, and the oxidation-resisting health-care food can be preserved for a long period of time.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of raising immunity, oxidation-resisting health-care food and preparation method thereof.
Background technology
Immunity is the defense mechanism of human body self, be human body identification and any foreign matter (virus, bacterium etc.) of eliminating external intrusion, process the ability of self cell and identification and processing vivo mutations cell and the virus infected cell of old and feeble, damage, death, sex change.Immune dysfunction or when low can reduce body to anti-infectious ability, reduces identification and removes the histocyte ability of self aging, reduces and kills and wounds and remove abnormal sudden change cell ability in vivo, causes the decline of human body premunition and vis medicatrix naturae.And modern society, the quickening of rhythm of life, the increase of competitive pressure, every day, the working and learning meeting of anxiety made body be in the overdraw state, as can not get having a rest timely and adjusting, and accumulated over a long period, will the Immunosuppression function; Simultaneously, nervous working and learning allow the more people instant fast food of having to, and cause the unbalance of endotrophic element, if body is in this state for a long time, immunity of organisms are descended, and finally cause the sub-health state of body.
The generation of biological interior free yl isoreactivity oxygen and cause the harm that the biological cell oxidative damage causes is one of major reason that causes Systemic aging.These free radicals comprise oxygen radical, hydroperoxyl radical and hydrogen peroxide etc., and they extensively are present in the body tissue.Unrighted acid in free radical attack cells film, the mitochondrial membrane causes lipid peroxidation to strengthen, and lipid peroxidation product can be decomposed into more free radical again, causes the chain reaction of free radical.Like this, the integrality of membrane structure is damaged, and causes the extensive injuries such as brain cell, muscle cell.
Therefore, take in to improve immunity health food and antioxidant functional food and be sought after, certainly, not only had the health food that improves immunity but also Wheat Protein then more practical if can provide a kind of.
Summary of the invention
Goal of the invention: the object of the invention is to for the deficiencies in the prior art, a kind of raising immunity, oxidation-resisting health-care food are provided.
Another object of the present invention is to provide the preparation method of above-mentioned health food.
Technical scheme: in order to reach the foregoing invention purpose, the present invention specifically is achieved like this: a kind of raising immunity, oxidation-resisting health-care food comprise the component of following percentage by weight: 15 ~ 35% the fruit of Chinese wolfberry, 15 ~ 35% the tuber of dwarf lilyturf, 10 ~ 30% Cordyceps sinensis, 10 ~ 30% ginseng and 5 ~ 20% the fruit of Chinese magnoliavine.
Wherein, the preferred natural cordyceps of described Cordyceps sinensis, paecilomycerol bat moth mycelium or Hirsutella sinensis mycelium.
Wherein, described health food can be made into the formulations such as capsule, pulvis, soft capsule, tablet or oral liquid.
Prepare the method for above-mentioned raising immunity, oxidation-resisting health-care food, may further comprise the steps:
(1) measures each raw material by prescription, pulverize, cross 80 mesh sieves;
(2) each raw material after will sieving mixes, and is prepared into capsule, pulvis, soft capsule or tablet.
Beneficial effect: it is raw material that the present invention adopts natural traditional Chinese medicine, when reaching raising immunity, antioxidation, can not have side effects, and is fit to all age group crowd; Simultaneously, preparation method of the present invention is simple, can not cause the variation of each feedstock property, can long preservation.
The specific embodiment
Embodiment 1:
Get the tuber of dwarf lilyturf, 30% the fruit of Chinese wolfberry, 30% Cordyceps sinensis, 20% ginseng and 5% the fruit of Chinese magnoliavine of percetage by weight 15%, pulverized 80 mesh sieves, the capsule of the 400mg that packs into.
Embodiment 2:
Get the tuber of dwarf lilyturf, 35% the fruit of Chinese wolfberry, 10% Cordyceps sinensis, 25% ginseng and 10% the fruit of Chinese magnoliavine of percetage by weight 20%, pulverized 80 mesh sieves, make the pulvis pack of 1g.
Embodiment 3:
Get the tuber of dwarf lilyturf, 20% the fruit of Chinese wolfberry, 15% Cordyceps sinensis, 30% ginseng and 10% the fruit of Chinese magnoliavine of percetage by weight 25%, pulverized 80 mesh sieves, compressing tablet becomes the tablet of 500mg.
Embodiment 4:
Get the tuber of dwarf lilyturf, 20% the fruit of Chinese wolfberry, 15% Cordyceps sinensis, 15% ginseng and 20% the fruit of Chinese magnoliavine of percetage by weight 30%, pulverized 80 mesh sieves, the soft capsule of the 400mg that packs into.
Embodiment 5:
Get the tuber of dwarf lilyturf, 15% the fruit of Chinese wolfberry, 25% Cordyceps sinensis, 10% ginseng and 15% the fruit of Chinese magnoliavine of percetage by weight 35%, pulverized 80 mesh sieves, add the oral liquid that 10 times of distilled water of raw material volume are made every of 10ml.
Embodiment 6:
The present invention increases the immunity function experimental study
1. material
1.1 sample: provided by three general pharmaceutcal corporation, Ltds.
1.2 animal used as test
160 of Kunming mouses, entirely female, body weight 18-22g.
2. experimental technique
2.1 dosage is selected
Tested material is established 400mg/kg.BW, 800mg/kg.BW, three dosage groups of 1200 mg/kg.BW (be equivalent to respectively human body recommended intake 10 times, 20 times, 30 times), take by weighing respectively 10.00g, 20.00g, 30.00g tested material adding distil water to the 250ml mixing, stored refrigerated, be finished again and join, other establishes the edible vegetable oil negative control group, every group of 40 animals.Be divided into immune one group, two groups, three groups, four groups, wherein one group is used for Turnover of Mouse Peritoneal Macrophages and engulfs the chicken red blood cell experiment; Two groups are used for NK cytoactive detection and lymphocyte transformation experiment; Three groups are used for antibody-producting cell experiment, serum hemolysin mensuration and delayed allergy; Four groups are used for mouse carbon and clean up experiment.Mouse gives 30 days continuously by per os gavage of 10 mg/kg.BW body weight, claims weekly body weight one time, adjusts the gavage volume.
2.2 experimental procedure
2.2.1 mouse carbon clearance test: gavage is after 30 days continuously, in the india ink of mouse tail vein injection with 4 times of normal saline dilutions, immediately timing after pressing 0.1ml/10g prepared Chinese ink and injecting is after injecting prepared Chinese ink the 2nd, 10min gets blood 20 μ l from the angular vein clump respectively, is added to 2mlNa
2CO
3In the solution, with Na
2CO
3Solution is made blank, measures OD value at the 600nm place with 723 spectrophotometers.Put to death mouse after getting blood, get liver, spleen is weighed, calculate phagocytic index.
2.2.2 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment (half intracorporal method): gavage is after 30 days continuously, the chicken erythrocyte suspension 1ml of every mouse peritoneal injection 20%, after 30 minutes, the cervical vertebra dislocation is put to death, be fixed on the mouse plate, abdominal skin is cut off in the center, through Intraperitoneal injection physiological saline 2ml, rotated the mouse plate 1 minute, sucking-off abdominal cavity washing lotion 1ml, mean droplet is on 2 slides, put 37 ℃ in wet box 30 minutes, and took out in the physiological saline rinsing, dry, fixing, 4%GiemsaPBS dyeing 3 minutes, the distilled water rinsing is dried, microscopy.Calculate phagocytic percentage and phagocytic index.
2.2.3 delayed allergy (DTH) (the sufficient sole of the foot thickens method): gavage is after 30 days, inject the every mouse of 2% hematocrit SRBC(0.2ml/ to mouse peritoneal) sensitization is after 4 days, measure left back sufficient sole of the foot thickness, and then measuring point hypodermic injection 20%(v/v) the every mouse of SRBC(20 μ l/), 24h measures left back sufficient sole of the foot thickness after injection, same position is measured three times, averages, and represents the degree of DTH with sufficient sole of the foot thickness difference (swelling degree of the paw) before and after attacking.
2.2.4ConA the mouse lymphocyte conversion test (mtt assay) of inducing: at first carry out the preparation of splenocyte suspension.Cell concentration is adjusted into 3 * 10
6Individual/ml, then cell suspension is divided two holes to add in 24 well culture plates, every hole 1ml, a hole adds 75 μ lConA liquid, and another hole compares, and puts 5%CO
237 ℃ of cultivations of incubator 72h.Cultivate and finish front 4h, every hole sucks gently supernatant 0.7ml and adds the RPMI1640 nutrient solution that 0.7ml does not contain calf serum, add simultaneously MTT (5mg/ml) 50 μ l/ holes and continue to cultivate 4h, after cultivating end, every hole adds 1ml acid isopropyl alcohol, purple crystal is dissolved fully, then every hole liquid is moved in the cuvette, with 723 spectrophotometers in 570nm wavelength place's colorimetric estimation OD value.
2.2.5 antibody-producting cell detects (Jernr improves slide method): gavage is after 30 days continuously, every mouse peritoneal is injected 2% hematocrit SRBC0.2ml, the mouse cervical vertebra dislocation of immunity after 5 days half put to death, take out spleen and be placed in the plate that fills Hank ' s liquid, make splenocyte suspension.Agarose is made into 1% aqueous solution, and 30min is boiled in water-bath, mix with the double Hank ' s of equivalent liquid, and the packing small test tube, every pipe 0.5ml adds 10%(S again in pipe
AThe buffer solution preparation) hematocrit SRBC50 μ l, each 20 μ l of splenocyte suspension do two Duplicate Samples, rapidly behind the mixing, be poured on the agarose thin layer slide, after agar solidifies, the slide level buckled be placed on the horse, put into CO2gas incubator and hatch 1.5h, then complement is joined in the slide frame groove, continue incubation 1.5h, counting hemolysis plaque number.
2.2.6 serum hemolysin is measured (Hemagglutination Method): in continuous gavage after 30 days, every mouse peritoneal injection 2%SRBC0.2ml immunity, continue gavage after 5 days, extract eyeball and get blood in centrifuge tube, place 1h, peel off, the centrifugal 10min of 2000r/min collects serum, with physiological saline serum is made doubling dilution, every part of dilution 12 holes place blood-coagulation-board with the dilution serum of difference, every hole 100 μ l, add again 0.5%SRBC suspension 100 μ l, mixing is put observed result behind wet 37 ℃ of 3h of box, records the aggegation degree in every hole.The calculating antibody product.
2.2.7NK cytoactive detection (lactate dehydrogenase L DH determination method): continuously gavage is after 30 days, and animal is put to death in the cervical vertebra dislocation, takes out spleen, tears up, cross 200 eye mesh screens after, use Hank ' s liquid to wash 3 times, be made into 2 * 10 with complete RPMI1640 nutrient solution
7Individual/the ml cell suspension.The cell suspension of each mouse is got 300 μ l divide 3 holes to place 96 well culture plates, every hole 100 μ l, every hole adds target cell (YAC-1 cell, 4 * 10
5Individual/ml) 100 μ l, do simultaneously each 8 hole of target cell Spontaneous release hole (target cell 100 μ l+ nutrient solutions 100 μ l) and maximum release aperture (target cell 100 μ l+2.5%Triton100 μ l), 37 ℃ of 5%CO
2Cultivated 4 hours, and took out the centrifugal 5min of 1500r/min.Each hole supernatant 100 μ l is placed another culture plate, and every hole adds 100 μ l matrix liquid again, adds the HCL30 μ l cessation reaction of 1mol/L after 10 minutes, measures the OD value at the 490nm place, calculates NK cytoactive rate.
3. test data is added up
Test data adopts SPSS10.0 for Windows software kit to process.The data of control group and dosage group are through the variance test of homogeneity, and variance is neat, carry out variance analysis,, then compare in twos with the Dunnett method less than 0.05 such as the P value; If heterogeneity of variance then carries out data transaction, and is still uneven, use rank test instead, less than 0.05, then use Dunnett ' sT3 method to compare in twos (P〉0.05 for non-significant difference, P＜0.05 is significant difference) such as the P value.
4. result
4.1 the present invention sees Table 1-4 to the impact of Mouse Weight.
Table 1 respectively organize mouse initial body weight (
)
Table 2 respectively organize mouse the body weight in mid-term (
)
Table 3 respectively organize mouse the end body weight (
)
The impact that table 4 the present invention increases weight on Mouse Weight (
)
By table 1-4 as seen, the initial body weight of one group, immune two groups of the present invention immunity, immune three groups and immune four groups of mouse is compared with negative control group, through the variance test of homogeneity, variance neat (P〉0.05), and the results of analysis of variance (P〉0.05), illustrate that the initial body weight of respectively organizing between mouse and the negative control group is balanced.Three dosage group mouse test mid-terms, the body weight in latter stage and the growths of duration of test Mouse Weight are compared with negative control group, learn by statistics and process, there was no significant difference (P〉0.05), i.e. the present invention on the body weight gain of mouse without impact.
4.2 the present invention is on the impact of mouse monokaryon-macrophage phagocytic function
Table 5 the present invention on mouse monokaryon-macrophage carbon clean up function impact (
)
By as seen from Table 5, gavage is after 30 days continuously, and the carbon of three dosage group mouse is cleaned up ability and compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05).
Table 6 the present invention on mouse macrophage engulf the chicken red blood cell ability impact (
)
By as seen from Table 6, gavage is after 30 days continuously, and the phagocytic rate of three dosage treated animals is compared with negative control group with phagocytic index, learns by statistics and processes, and middle and high dosage group phagocytic index has significant difference (P＜0.05).
By table 5, as seen from Table 6, the present invention is positive to mouse monokaryon-macrophage phagocytic function test result.
4.3 the present invention is on the impact of mouse cell immunity
Table 7 the present invention on the impact of mouse delayed allergy (DTH) (
)
By as seen from Table 7, gavage is after 30 days continuously, and the swelling degree of the paw of three dosage group mouse is compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05)
The impact of the mouse lymphocyte conversion test that table 8 the present invention induces ConA (
)
By as seen from Table 8, the gavage mouse is after 30 days continuously, and the lymphopoiesis ability of three dosage group mouse is compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).
By table 7, the present invention is negative to mouse cell immunity test result as seen from Table 8.
4.4 the present invention is on the impact of mouse humoral immune
Table 9 the present invention on the impact of mouse antibodies cellulation (
)
By as seen from Table 9, gavage is after 30 days continuously, and the hemolysis plaque number of three dosage group mouse is compared with negative control, learns by statistics and processes, and low, middle dosage group has significant difference (P＜0.05).
Table 10 the present invention on the impact of mice serum hemolysin (
)
By as seen from Table 10, gavage is after 30 days continuously, and the antibody product of three dosage group mouse is compared with negative control group, learns by statistics and processes, and low dose group has utmost point significant difference (P＜0.05)
By table 9, as seen from Table 10, the present invention is positive to the mouse humoral immune result of the test.
4.5 the present invention is on the impact of NK cells in mice activity
Table 11 the present invention on the impact of NK cells in mice activity (
)
By as seen from Table 11, gavage is after 30 days continuously, and three dosage group NK cells in mice activity are compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).The present invention is aobvious negative to the NK cytoactive result of the test of mouse.
5. sum up
The continuous gavage mouse of the present invention had no significant effect Mouse Weight after 30 days; Test for celluar immunity result to mouse is negative; NK test cell line result to mouse is negative; To the test for humoral immunity of mouse, the hemolysis plaque number of three dosage groups and negative control group compare, and low, middle dosage group difference all has conspicuousness (P＜0.05), and result of the test is positive; To the monocytes/macrophages phagocytic function test of mouse, the phagocytic rate of three dosage group mouse and phagocytic index and negative control group compare, and middle and high dosage group difference has conspicuousness (P＜0.05), and result of the test is positive.
Can judge according to " health food check and assessment technique standard " version in 2003, the present invention has the function that increases immunity to animal.
Embodiment 7:
The experiment of antioxidation of the present invention (animal experiment)
1, sample
Provided by S﹠P Pharmaceutical Co., Ltd.
2, animal used as test
40 of Wistar kind male rats, body weight 473.3 ± 59.6g.
3, dosage is selected to give mode with tested material
Human body recommended amounts per sample establishes 800,400,200mg/kgBW(is equivalent to respectively human body and recommends 20,10,5 times of consumption) 3 dosage groups, establish simultaneously a negative control group, every group of 10 animals.Take by weighing content 80.0g of the present invention, adding distil water is to 1000mL, dissolving, mixing are made into 80.0mg/ml concentration solution, again with distilled water successively two-fold dilution become 40.0,20.0mg/ml concentration, adopt the per os mode, give respectively corresponding dosage treated animal gavage, the gavage volume is 1.0ml/100gBW, and negative control group gives isopyknic distilled water, every day gavage once, continuously gavage is 60 days.
4, experimental technique
Tested rat was fed 5 days, and the intraocular corner of the eyes is got hematometry Serum MDA (MDA) content behind the no abnormality seen.According to MDA content the rat stratified random is divided into 4 groups, 10 every group, and suitably adjust, be that the average weight of each group is also balanced as much as possible.Press the volume of 1.0mL/100gBW, give respectively the sample solution of corresponding dosage treated animal gavage respective concentration, negative control group gives isopyknic distilled water, every day gavage once, continuously gavage is 60 days, then puts to death animal, gets blood, liver, brain tissue and carries out observation index and measure.
4.1 LPO assay in rat blood serum and liver, the brain tissue homogenate (with the MDA content meter).
4.2 antioxidase in rat blood serum and liver, the brain tissue homogenate (GSH-Px and SOD) vitality test.
4.3 lipofuscin (Lip) assay in rats'liver, the brain tissue homogenate's liquid.
5, result of the test
5.1 the present invention is on the impact of rat body weight
Respectively organize the rat body weight no significant difference before the test, the body weight of test mid-term and each dosage group rat of off-test the present invention and weightening finish and negative control group are relatively, there are no significant for difference (P〉0.05), show that the present invention has no significant effect the body weight of rat, sees Table 12.
Table 12 duration of test respectively organize rat changes of weight (
)
5.2 the present invention is on rat blood serum and organize the active impact of antioxidase (SOD and GSH-Px)
5.2.1 the present invention is on the impact of superoxide dismutase activity in rat blood serum and the tissue
Table 13 respectively organize the serum of rat and liver, brain tissue SOD content (
)
| The dosage group | Number of animals | SOD in serum | The P value | Brain tissue SOD | The P value | Hepatic tissue SOD | The P value |
| mg/kg·BW | (only) | （NU/ml） | (NU/g tissue) | (NU/g tissue) | |||
| 800 | 10 | 183.5±2.1 | 0.048 | 914.1±48.9 | 0.000 | 1539.8±49.8 | 0.001 |
| 400 | 10 | 182.1±8.4 | 0.158 | 825.9±105.9 | 0.187 | 1445.4±108.4 | 0.135 |
| 200 | 10 | 181.4±4.8 | 0.252 | 848.8±79.3 | 0.053 | 1491.9±76.6 | 0.015 |
| Negative control | 10 | 177.2±5.8 | 758.6±87.3 | 1351.3±157.8 |
By as seen from Table 13, the SOD vigor all is higher than negative control group in the serum of each dosage group rat of the present invention and liver, the brain tissue, wherein the difference of the serum of high dose group, brain tissue, hepatic tissue SOD vigor and negative control group all have conspicuousness (P 0.01 or P 0.05), the difference of low dose group hepatic tissue SOD vigor and negative control group has conspicuousness (P＜0.05), shows that the present invention has to improve rat serum and organize the active effect of superoxide dismutase (SOD).
5.2.2 the present invention is on the impact of rat tissue's Glutathione Peroxidase (GSH-Px) vigor
Table 14 respectively organize the serum of rat and liver, brain tissue (GSH-Px) vigor impact (
)
| The dosage group | Number of animals | GSH-Px in serum | The P value | Brain tissue GSH-Px | The P value | Hepatic tissue GSH-Px | The P value |
| mg/kg·BW | (only) | （NU/ml） | (NU/g tissue) | (NU/g tissue) | |||
| 800 | 10 | 47.1±4.9 | 0.027 | 589.0±155.6 | 0.061 | 1842.3±188.0 | 0.912 |
| 400 | 10 | 49.6±3.3 | 0.005 | 525.6±75.3 | 0.430 | 1863.4±314.2 | 0.855 |
| 200 | 10 | 56.6±10.0 | 0.000 | 637.6±8.4 | 0.009 | 2202.3±449.2 | 0.042 |
| Negative control | 10 | 37.2±11.5 | 447.5±99.7 | 1746.8±561.0 |
By as seen from Table 14, the GSH-Px vigor all is higher than negative control group in the serum of each dosage group rat of the present invention and liver, the brain tissue, wherein in the serum of each dosage group rat the difference of GSH-Px vigor and negative control group all have conspicuousness (P 0.01 or P 0.05), the difference of the brain of low dose group and hepatic tissue GSH-Px vigor and negative control group have conspicuousness (respectively P 0.01 and P 0.05), surperficial the present invention has the effect of glutathione peroxidase (GSH-Px) vigor that improves rat serum and tissue.
5.2.3 the present invention is on rat blood serum and organize the impact of lipid peroxide (LPO) content
Table 15 respectively organize the serum of rat and brain tissue lipid peroxide (LPO is in MDA) content (
)
By as seen from Table 15, the Serum LPO content of each treated animal is balanced before the test, and each organizes no significant difference (P〉0.05).Test eventually lipid peroxide (LPO) content of serum, brain and the hepatic tissue of each dosage group rat of last the present invention all is lower than negative control group, wherein the difference of the hepatic tissue LPO of each dosage group and negative control group have conspicuousness (P 0.01 or P 0.05), the Serum LPO of high, middle dosage group and the difference of negative control group have conspicuousness (P＜0.05), show that the present invention has the effect that reduces LPO in rat blood serum and the tissue.
5.2.4 the present invention is on the impact of rat tissue's lipofuscin (Lip) content
The results are shown in Table 16, the hepatic tissue lipofuscin content of each dosage group rat of the present invention all is lower than negative control group, wherein, the difference of the hepatic tissue lipofuscin content of low dose group rat and negative control group have conspicuousness (respectively P 0.05 and P 0.01), the brain tissue lipofuscin content of high dose group and the difference of negative control group have conspicuousness (P＜0.05), show that the present invention has the effect that reduces the lipofuscin content in the tissue.
Lipofuscin in table 16 rat tissue (Lip) content (
)
| The dosage group | Number of animals | Hepatic tissue Lip | The P value | Brain tissue Lip | The P value |
| mg/kg·BW | (only) | μ g/g tissue | μ g/g tissue | ||
| 800 | 10 | 24.5±10.6 | 0.248 | 35.7±19.2 | 0.030 |
| 400 | 10 | 17.4±12.1 | 0.021 | 47.8±15.3 | 0.406 |
| 200 | 10 | 11.6±8.4 | 0.002 | 44.7±21.8 | 0.237 |
| Negative control | 10 | 34.5±20.1 | 60.0±23.8 |
6, brief summary
Respectively with 800,400, the present invention of 200mg/kg BW dosage (be equivalent to respectively human body and recommend 20,10,5 times of consumption) gives the continuous gavage of rat 60 days, lipofuscin content in lipid peroxide (LPO) in reducing rat blood serum and organizing and the tissue, improve the activity of the superoxide dismutase (SOD) in rat blood serum and the tissue and the vigor of glutathione peroxidase (GSH-Px), body weight to rat has no significant effect, and surperficial the present invention has oxidation resistant function.
The experiment of antioxidation of the present invention (human trial)
7, material
Content of the present invention, specification are the 0.4g/ grain, and the human body recommended amounts is everyone (adult) every day 2 times, each 3.Room temperature preservation.Placebo outward appearance, color and luster, size, specification, instructions of taking, consumption, packing and title are identical with the present invention.
8, study subject
Age, physical condition was good at 45 ~ 65 years old, without obvious brain, the heart, liver, lung, kidney, Hematological Diseases, without the Long-term taking medicine history, volunteered tested and assurance cooperation person.This test initially has 112 volunteers and participates in test.
9, experimental design
Adopt between self and group two kinds facing to design.Be divided at random test group and control group by experimenter's serum MDA, SOD, GSH-Px level, every group of each 56 people.The test eventually last number that enters effective statistics of respectively organizing should be no less than 50 examples.Test group test-meal sample everyone every day 2 times (early 7 evenings 8 each once), each 3, control group adopts placebo, the same test group of quantity and method.Took continuously 4 months, two groups of former lives of crowd of duration of test, diet are constant.
10, its functional attributes
10.1 LPO: variation and the MDA decline percentage of MDA before and after the viewing test.MDA * 100% before MDA decline percentage (%)=(the rear MDA of MDA-test before the test)/test
10.2 superoxide dismutase: variation and the SOD rising percentage of SOD before and after the viewing test.SOD * 100% before SOD rising percentage (%)=(the front SOD of SOD-test after the test)/test
10.3 glutathione peroxidase dismutase activity: variation and the GSH-Px rising percentage of GSH-Px before and after the viewing test.GSH-Px * 100% before GSH-Px rising percentage (%)=(the front GSH-Px of GSH-Px-test after the test)/test
11, test data statistical disposition
The own control data adopts paired t-test.Two groups of means relatively adopt in groups t check.Percentage x
2Check is tested.Before test between two groups under the prerequisite of comparing difference without conspicuousness, after can testing between two groups relatively.
12, the result judges
Between group statistical significance is arranged relatively after each functional observation index Test front and back self comparison and the test-meal, can judge that this index is positive.
Each result is positive in LPO, superoxide dismutase activity, three indexs of activity of glutathione peroxidase, can judge the concrete anti-oxidation function effect of the present invention.
13, result
13.1 ordinary circumstance: test eventually end is not rechecked because of the minority experimenter, and control group and test group respectively have 51 examples to enter effective statistics.Losing the visit rate is 8.92%.Before the test-meal, test group and control group crowd's age, mental status, sleep quality, diet situation are basically identical; Two groups of crowds' fluoroscopy of chest, electrocardiogram and Abdominal B type ultrasonography check result are showed no obvious abnormalities.The front two groups of crowds' of test-meal LPO, superoxide dismutase activity and activity of glutathione peroxidase relatively all do not have notable difference (P〉0.05), see Table 17.
The front two groups of crowd's basic conditions of table 17 test-meal (
)
13.2 the present invention is on the impact of Serum Lipid Peroxide
The front two groups of crowds' of test-meal Serum LPO Levels (MDA) content no significant difference (P〉0.05).After the test-meal, test group crowd's Serum Lipid Peroxide is starkly lower than control group, and rate of descent is also obviously greater than control group, and difference all has conspicuousness (P＜0.01); Serum Lipid Peroxide after the simultaneously test group test-meal obviously reduces before than test-meal, and difference has conspicuousness (P＜0.01), shows that the present invention has the effect of the Serum Lipid Peroxide that reduces the examination trencherman, sees Table 18.
Two groups of crowds' Serum Lipid Peroxide variation before and after table 18 test-meal (
)
| Group | Number | MDA before the examination | MDA after the examination | Drop-out value | Rate of descent | P value (self) |
| （nmol/ml） | （nmol/ml） | （nmol/ml） | （%） | |||
| Control group | 51 | 5.03±0.94 | 4.95±0.89 | 0.08±0.76 | 0.59±15.07 | P〉0.05 |
| Test group | 51 | 5.22±0.90 | 4.57±0.86 | 0.65±0.57 | 12.06±10.32 | P〈0.01 |
| P value (between group) | P〉0.05 | P〈0.05 | P〈0.01 | P〈0.01 |
13.3 the present invention is on the active impact of serum superoxide dismutases (SOD)
The front two groups of crowds' of test-meal the active no significant difference of serum superoxide dismutases (SOD) (P〉0.05).After the test-meal, the active lift-off value of test group crowd's serum superoxide dismutases (SOD) and rate of rise all are a bit larger tham control group, but there are no significant for difference (P〉0.05), shows do not raise examination trencherman's serum superoxide dismutases (SOD) active function of the present invention, sees Table 19.
Two groups of crowds' serum superoxide dismutases activity change before and after table 19 test-meal (
)
| Group | Number | SOD before the examination | SOD after the examination | Lift-off value | Rate of rise | P value (self) |
| （NU/ml） | （NU/ml） | （NU/ml） | （%） | |||
| Control group | 51 | 83.73±14.21 | 84.23±14.57 | 0.50±5.12 | 0.72±6.06 | P〉0.05 |
| Test group | 51 | 81.84±15.73 | 84.53±16.17 | 2.68±7.68 | 3.90±9.58 | P〉0.05 |
| P value (between group) | P〉0.05 | P〉0.05 | P〉0.05 | P〉0.05 |
13.4 the present invention is on the active impact of serum glutathione peroxidase (GSH-Px)
The front two groups serum activity of glutathione peroxidase no significant difference of test-meal (P〉0.05).After the test-meal, the serum activity of glutathione peroxidase of test group is higher than control group, but two groups of no significant differences (P〉0.05); Test group lift-off value, rate of rise be all greater than control group, and difference all has conspicuousness (P＜0.01); But serum activity of glutathione peroxidase self there are no significant difference before and after two groups of test-meals (P〉0.05), show that the present invention has certain effect to the examination trencherman serum activity of glutathione peroxidase that raises, but be not clearly, see Table 20.
Two groups of crowds' serum activity of glutathione peroxidase variation before and after table 20 test-meal (
)
| Group | Number | GSH-Px before the examination | GSH-Px after the examination | Lift-off value | Rate of rise | P value (self) |
| （NU/ml） | （NU/ml） | （NU/ml） | （%） | |||
| Control group | 51 | 113.66±15.16 | 113.98±17.01 | 0.32±6.95 | 0.21±6.19 | P〉0.05 |
| Test group | 51 | 111.81±16.31 | 116.70±15.56 | 4.89±8.88 | 4.89±8.49 | P〉0.05 |
| P value (between group) | P〉0.05 | P〉0.05 | P〈0.01 | P〈0.01 |
14, brief summary
Meet this age of testing tested selected mark 45 ~ 65 years old crowd's 102 example.Wherein test group 51 examples are taken the present invention after 4 months continuously, and Serum Lipid Peroxide on average descends and compares with control group and to have significant difference (P＜0.05), and self difference has conspicuousness (P＜0.01) before and after the test-meal.Test group glutathione peroxidase (GSH-Px) is active on average to raise and has compared significant difference (P＜0.01) with control group, but test front and back self no significant difference (P〉0.05), show that the present invention has certain effect to GSH-Px, but not clearly.This shows, the present invention has the anti-oxidation function effect.
15, sum up
From animal experiment and human experiment interpretation of result, and can judge according to " health food check with assessment technique standard " version in 2003, the present invention has anti-oxidation function.
Claims (4)
1. one kind is improved immunity, oxidation-resisting health-care food, it is characterized in that, comprises the component of following percentage by weight: 15 ~ 35% the fruit of Chinese wolfberry, 15 ~ 35% the tuber of dwarf lilyturf, 10 ~ 30% Cordyceps sinensis, 10 ~ 30% ginseng and 5 ~ 20% the fruit of Chinese magnoliavine.
2. raising immunity according to claim 1, oxidation-resisting health-care food is characterized in that, described Cordyceps sinensis is natural cordyceps, paecilomycerol bat moth mycelium or Hirsutella sinensis mycelium.
3. raising immunity according to claim 1 and 2, oxidation-resisting health-care food is characterized in that, the formulation of described health food is capsule, pulvis, soft capsule, tablet or oral liquid.
4. prepare the method for the described arbitrary raising immunity of claim 1 ~ 3, oxidation-resisting health-care food, it is characterized in that, may further comprise the steps:
(1) measures each raw material by prescription, pulverize, cross 80 mesh sieves;
(2) each raw material after will sieving mixes, and is prepared into capsule, pulvis, soft capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210379884.7A CN102860496B (en) | 2012-10-09 | 2012-10-09 | Oxidation-resisting health-care food for improving immunity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210379884.7A CN102860496B (en) | 2012-10-09 | 2012-10-09 | Oxidation-resisting health-care food for improving immunity and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102860496A true CN102860496A (en) | 2013-01-09 |
| CN102860496B CN102860496B (en) | 2015-06-03 |
Family
ID=47439848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210379884.7A Active CN102860496B (en) | 2012-10-09 | 2012-10-09 | Oxidation-resisting health-care food for improving immunity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102860496B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103005449A (en) * | 2013-01-14 | 2013-04-03 | 王跃进 | Medlar soft capsule enriched nutriment |
| CN104187623A (en) * | 2014-08-07 | 2014-12-10 | 温素丽 | Health food for improving immunity |
| CN104799361A (en) * | 2014-03-19 | 2015-07-29 | 杨邱月 | Health-care soup for improving postoperative immunity of tumor patient |
| CN106138680A (en) * | 2015-04-03 | 2016-11-23 | 金士力佳友(天津)有限公司 | A kind of Chinese medicine composition with anti-oxidation function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872277A (en) * | 2005-06-03 | 2006-12-06 | 天津天士力制药股份有限公司 | Application of medication composition of containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain |
| CN101011528A (en) * | 2007-02-01 | 2007-08-08 | 四川美大康药业股份有限公司 | Chinese medicine preparation for boosting qi and nourishing yin, nourishing blood and promoting blood circulation, and its preparation method |
| CN101912522A (en) * | 2010-07-28 | 2010-12-15 | 四川美大康药业股份有限公司 | Detection method of Liuweisheng tablets |
| CN102293430A (en) * | 2011-06-24 | 2011-12-28 | 于光远 | Beverage with functions of antioxidation and immunity enhancing, and preparation method thereof |
-
2012
- 2012-10-09 CN CN201210379884.7A patent/CN102860496B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872277A (en) * | 2005-06-03 | 2006-12-06 | 天津天士力制药股份有限公司 | Application of medication composition of containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain |
| CN101011528A (en) * | 2007-02-01 | 2007-08-08 | 四川美大康药业股份有限公司 | Chinese medicine preparation for boosting qi and nourishing yin, nourishing blood and promoting blood circulation, and its preparation method |
| CN101912522A (en) * | 2010-07-28 | 2010-12-15 | 四川美大康药业股份有限公司 | Detection method of Liuweisheng tablets |
| CN102293430A (en) * | 2011-06-24 | 2011-12-28 | 于光远 | Beverage with functions of antioxidation and immunity enhancing, and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 申玲玲等: "冬虫夏草的药理作用", 《中国医院药学杂志》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103005449A (en) * | 2013-01-14 | 2013-04-03 | 王跃进 | Medlar soft capsule enriched nutriment |
| CN103005449B (en) * | 2013-01-14 | 2014-07-16 | 王跃进 | Medlar soft capsule enriched nutriment |
| CN104799360B (en) * | 2014-03-19 | 2016-09-21 | 南阳医学高等专科学校 | Improve the health promoting decoction of tumor patient Postoperative Immunity function |
| CN104799361A (en) * | 2014-03-19 | 2015-07-29 | 杨邱月 | Health-care soup for improving postoperative immunity of tumor patient |
| CN104872740A (en) * | 2014-03-19 | 2015-09-02 | 杨邱月 | Health soup capable of improving post-operation immunity of cancer patients |
| CN104886673A (en) * | 2014-03-19 | 2015-09-09 | 杨邱月 | A preparation method of health-care soup for improving postoperative immune function of tumor patients |
| CN104872740B (en) * | 2014-03-19 | 2016-10-19 | 贾玉臻 | A kind of health promoting decoction improving tumor patient Postoperative Immunity power |
| CN104799291B (en) * | 2014-03-19 | 2016-11-23 | 北京嘉捷美锦科技发展有限公司 | One improves tumor patient Postoperative Immunity functional health soup |
| CN104886673B (en) * | 2014-03-19 | 2017-01-04 | 山东钟冠海洋生物科技有限公司 | Preparation method of health soup for improving postoperative immune function of tumor patient |
| CN104799361B (en) * | 2014-03-19 | 2017-02-08 | 高磊 | Health-care soup for improving postoperative immunity of tumor patient |
| CN104187623A (en) * | 2014-08-07 | 2014-12-10 | 温素丽 | Health food for improving immunity |
| CN106138680A (en) * | 2015-04-03 | 2016-11-23 | 金士力佳友(天津)有限公司 | A kind of Chinese medicine composition with anti-oxidation function |
| CN106138680B (en) * | 2015-04-03 | 2021-05-11 | 金士力佳友(天津)有限公司 | Traditional Chinese medicine composition with antioxidant function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102860496B (en) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169079A (en) | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof | |
| CN102204678B (en) | Instant cubilose powder with efficacy of immunity enhancement and preparation method thereof | |
| CN105310075A (en) | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid | |
| CN101940313B (en) | Health food capable of enhancing immunity of human body and preparation method thereof | |
| CN103829234A (en) | Health food capable of improving immunity and reducing blood fat and preparation method thereof | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN104857088A (en) | Preparation method of mulberry leaf compound capsule for lowering blood glucose in assistant manner | |
| CN102960715A (en) | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof | |
| CN102871120A (en) | Heath-care food for improving human immunity and preparation method thereof | |
| CN102429150A (en) | Vitamin C chewable tablets for enhancing human immunity | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN107343889A (en) | A kind of peacilomyce hepiahi bacterium fermentation culture medium for being used to treat the 1st type or diabetes B | |
| CN1785054A (en) | Health-care food having anti-oxidation function and its prepn. method | |
| CN106923334A (en) | A kind of astaxanthin flexible glue capsule formula and preparation method thereof | |
| CN103039977A (en) | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof | |
| CN106728387B (en) | Compound medicine with function of promoting immunity and preparation method thereof | |
| CN102860495B (en) | Anti-anoxia immunity-improving health food and preparation method thereof | |
| CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
| CN102860509A (en) | Anti-fatigue immunity-improving health food and preparation method thereof | |
| CN102406172B (en) | Health-care food for enhancing immunity and preparation method thereof | |
| CN100391476C (en) | Medicine composition for delaying senility and raising immunity and its prepn | |
| CN104189038A (en) | Traditional Chinese medicine preparation for regulating female physical health and immunity | |
| CN104906145A (en) | Medical application of paecilomyces hepiali mutant strain PH40 in treating diabetes | |
| CN102871119A (en) | Health-care food with anti-anoxia effect and preparation method thereof | |
| CN112107603A (en) | Application of hericium erinaceus solid culture extract in preparation of composition for delaying aging and treating Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: S + P PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: S+P PHARMACEUTICAL CO., LTD. Effective date: 20130916 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20130916 Address after: 810007 Qinghai province Xining City Chengdong District No. 58 Delingha Road Applicant after: S&P Pharma Co., Ltd. Address before: 810007 Qinghai province Xining City Chengdong District No. 58 Delingha Road Applicant before: S & P Pharmaceutical Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |